Design and Optimization of Sulfone Pyrrolidine Sulfonamide Antagonists of Transient Receptor Potential Vanilloid-4 with in Vivo Activity in a Pulmonary Edema Model.
|
| Abstract |
Pulmonary edema is a common ailment of heart failure patients and has remained an unmet medical need due to dose-limiting side effects associated with current treatments. Preclinical studies in rodents have suggested that inhibition of transient receptor potential vanilloid-4 (TRPV4) cation channels may offer an alternative-and potentially superior-therapy. Efforts directed toward small-molecule antagonists of the TRPV4 receptor have led to the discovery of a novel sulfone pyrrolidine sulfonamide chemotype exemplified by lead compound 6. Design elements toward the optimization of TRPV4 activity, selectivity, and pharmacokinetic properties are described. Activity of leading exemplars 19 and 27 in an in vivo model suggestive of therapeutic potential is highlighted herein.
|
|---|---|
| Authors | Joseph E Pero, Jay M Matthews, David J Behm, Edward J Brnardic, Carl Brooks, Brian W Budzik, Melissa H Costell, Carla A Donatelli, Stephen H Eisennagel, Karl Erhard, Michael C Fischer, Dennis A Holt, Larry J Jolivette, Huijie Li, Peng Li, John J McAtee, Brent W McCleland, Israil Pendrak, Lorraine M Posobiec, Katrina L K Rivera, Ralph A Rivero, Theresa J Roethke, Matthew R Sender, Arthur Shu, Lamont R Terrell, Kalindi Vaidya, Xiaoping Xu, Brian G Lawhorn |
| Journal | Journal of medicinal chemistry (J Med Chem) Vol. 61 Issue 24 Pg. 11209-11220 (12 27 2018) ISSN: 1520-4804 [Electronic] United States |
| PMID | 30500190 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!